We tested 16 million SNPs, identified through whole-genome sequencing of 457 Icelanders, for association with gout and serum uric acid levels. Genotypes were imputed into 41,675 chip-genotyped Icelanders and their relatives, for effective sample sizes of 968 individuals with gout and 15,506 individuals for whom serum uric acid measurements were available. We identified a low-frequency missense variant (c.1580C>G) in ALDH16A1 associated with gout (OR = 3.12, P = 1.5 × 10 −16 , at-risk allele frequency = 0.019) and serum uric acid levels (effect = 0.36 s.d., P = 4.5 × 10 −21 ). We confirmed the association with gout by performing Sanger sequencing on 6,017 Icelanders. The association with gout was stronger in males relative to females. We also found a second variant on chromosome 1 associated with gout (OR = 1.92, P = 0.046, at-risk allele frequency = 0.986) and serum uric acid levels (effect = 0.48 s.d., P = 4.5 × 10 −16 ). This variant is close to a common variant previously associated with serum uric acid levels. This work illustrates how whole-genome sequencing data allow the detection of associations between low-frequency variants and complex traits.
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Gout is a common inflammatory arthritis 1,2 caused by urate crystal formation resulting from a high concentration of uric acid in the blood, which is in turn caused by an imbalance in the dietary intake of purines and in the synthesis and excretion of urate. The incidence of gout increases with age and is three times higher in men than in women 2 . The prevalence of gout is 5% in individuals over the age of 65 (ref. 2) . The most common prophylactic treatment for recurrent attacks of gout is allopurinol, an inhibitor of uric acid synthesis 3 .
Genome-wide association studies (GWAS) of serum uric acid levels have identified associations with sequence variants at several loci. Initially, a variant at SLC2A9 (also known as GLUT9) was shown to have a large effect on serum uric acid levels [4] [5] [6] [7] . Two meta-analyses yielded variants at nine loci that associate significantly with serum uric acid levels 8, 9 and also associate with gout 9 . Altogether, the eight sequence variants reported by the CHARGE consortium explain 6.0% of the variance of serum uric acid levels 9 . The heritability of serum uric acid levels has been estimated to be ~40% 10, 11 , consistent with our estimate of 36%, based on 13,240 Icelandic full-sibling pairs.
We have sequenced 457 Icelanders to an average depth of at least 10× (Supplementary Fig. 1 ). The 15,957,390 SNPs identified were then imputed into 41,675 chip-genotyped Icelanders using long-range phasing 12 . The Icelandic genealogical database allowed us to propagate genotype information and create in silico genotypes for relatives of the chip-genotyped individuals (see Online Methods). We then tested for association between these SNPs and both serum uric acid levels and gout. A total of 789 Icelandic individuals with gout have been chipgenotyped ( Table 1 ). An additional 381 cases without chip information were assigned in silico genotypes, corresponding to an effective sample size increase of 179 subjects. This corresponds to an overall effective sample size of 968 subjects with gout and over 40,000 control subjects. The chip-genotyped data set contains 11,351 Icelanders with measurements of serum uric acid levels. This data set was also augmented with 9,404 in silico-genotyped individuals with serum uric acid measurements, corresponding to an effective sample size increase of 4,155 individuals. This corresponds to an overall effective sample size of 15,506 individuals with serum uric acid measurements.
l e t t e r s
The gout GWAS yielded significant association (P < 0.05 divided by 16 million = 3 × 10 −9 ) with SNPs at two loci: 4q22.1 and 19q13 (see quantile-quantile plot in Supplementary Fig. 2 ). The most significant association with gout was with the G allele of a SNP at position 54,660,818 on chromosome 19 (build 36 assembly) (odds ratio (OR) = 3.12, P = 1.54 × 10 −16 , allelic frequency of 1.8% in control subjects). This polymorphism is not reported in the dbSNP Build 132 release. The SNP is in an exon of the aldehyde dehydrogenase 16 family, member A1 (ALDH16A1) gene. It is located in exon 13, c.1580C>G, of the 17-exon transcript and in exon 12, c.1427C>G, of the 16-exon transcript and leads to a missense proline to arginine alteration of amino acids 527 (p.Pro527Arg) and 476 (p.Pro476Arg) in NP_699160 and NP_001138868, respectively. This SNP will be referred to as c.1580C>G throughout the manuscript. Eighteen other SNPs on 19q13 reached a P < 5 × 10 −8 , spanning 1.3 Mb (Fig. 1 and Supplementary Table 1) . None of the 19 markers are in HapMap 2 or 3.
We examined small (<20-bp) inserts and deletions (indels) in a 4-Mb region around ALDH16A1 among the 457 sequenced individuals, including the 19 carriers of c.1580C>G. We observed a total of 311 indels in coding exons and 344 in the untranslated regions of genes. Of these indels, 78 were present in c.1580C>G carriers and none occurred in more than three. After conditioning for the effect of c.1580C>G on gout, no other marker at the 19q13 locus remained significantly associated with gout ( Fig. 1) .
We note that there are a number of genes at the 19q13 locus, including SLC17A7, a member of a transporter family implicated in urate homeostasis 8, 9 . Sequence variants on chromosome 6, in a cluster of members of the SLC17 gene family (SLC17A1-SLC17A4), have also been reported to associate with serum uric acid levels and gout 8, 9 .
ALDH16A1 is a member of the aldehyde dehydrogenase (ALDH) superfamily 13 and is widely expressed 14 . ALDHs are metabolic enzymes that catalyze reactions involving a wide spectrum of endogenous and exogenous aldehydes 13, 15 . Polymorphisms in ALDH genes have been associated with several diseases 16 . A sequence variant in the ALDH2 gene (ALDH2*2) has been associated with predisposition to alcohol-induced flushing reaction and protection against excessive alcohol consumption 17 . Alcohol enhances adenine nucleotide degradation and some beverages are rich in purines; consequently, the ALDH2*2 variant protects against alcohol-induced hyperuricemia and gout in East Asians 17, 18 . At least two members of the ALDH superfamily have been implicated in purine metabolism, and we postulate that ALDH16A1 also plays a role in this process.
The most significant association with gout at 4q22.1 is with rs2231142-T (OR = 1.66, P = 2.82 × 10 −12 , allele frequency = 15%). This SNP codes for a glutamine to lysine alteration at position 141, p.Gln141Lys in the ATP-binding cassette, subfamily G, member 2 (ABCG2) gene and has been reported to associate with serum uric acid levels and gout 8, 9, 19 ( Fig. 1 and Supplementary Table 2) .
The GWAS yielded significant association (P < 3 × 10 −9 ) between serum uric acid levels and SNPs at four loci (see quantile-quantile plot in Supplementary Fig. 3 ). SNPs at the highest and third-ranked loci correspond to previously reported signals at SLC2A9 and ABCG2. The best SNP at the second-ranked locus is the newly discovered c.1580C>G variant in ALDH16A1 described above, which is estimated to explain 0.5% of the population variance in serum uric acid levels. The SNPs at the fourth-ranked locus flank the centromere of chromosome 1 (120-145 Mb), close to variants previously reported to associate with serum uric acid levels 8, 9 ( 
In the present analysis, the best SNP at this locus is located at position 142,697,422 (build 36 assembly and referred to as chr1_142697422).
In the Icelandic population, the frequency with which the chr1_ 142697422 allele associates with higher serum uric acid levels is greater than for the reported SNP (98.6% versus 50.0%), the effect is stronger (0.48 versus 0.04 s.d.), the significance is greater (P = 4.5 × 10 −16 versus P = 0.0012), and the two markers have low correlation (r 2 = 0.0080). These findings suggest that the reported variants are not capturing the whole signal at this locus and that rare variants represented by chr1_ 142697422 have an effect on serum uric acid levels. The association of the reported SNP with serum uric acid levels remained significant after adjusting for chr1_142697422 (P = 0.0052). We estimate the fraction of the population variance of serum uric acid levels explained by this new variant to be 0.6%. The allele of chr1_142697422 associated with higher serum uric acid levels also has a nominally significant association with gout (OR = 1.92; P = 0.046), and the disease effect is confined to males ( Fig. 2 and Supplementary Tables 4 and 5) . Localization of the chromosome 1 signal is challenging, as the centromere is poorly covered by the SNP chip used to impute the SNPs identified through sequencing. Consequently, the imputation information of the strongest-associating SNP on chromosome 1 is only 0.55. The low recombination rate around the centromere also makes localization more difficult.
The association results of c.1580C>G presented above were based on imputation. In order to confirm the results, we performed Sanger sequencing of this position in 1,094 subjects with gout and 4,923 control subjects. The majority of the subjects were already included in the GWAS described above. In this directly genotyped set, the association between gout and c.1580C>G reached a significance level of 2.6 × 10 −19 , with an OR of 3.72 (95% confidence interval (CI) 2.79-4.96) and allele frequencies of 4.7% in individuals with gout and 1.3% in control subjects.
In addition to the C and G alleles at position 54,660,818 of chromosome 19, we observed a rarer third allele (A) that occurred in 9 out of the 6,017 individuals genotyped directly. Given the extremely low frequency of this allele, we currently cannot draw any conclusions regarding its association with serum uric acid levels or gout.
Comparing the allele count between the imputed and directly sequenced genotypes for c.1580C>G, we observed an r 2 We Sanger sequenced c.1580C>G in other populations and observed 7 carriers from 3,948 individuals (Norway 4/532; Denmark 1/1,538; The Netherlands 1/1,024; USA 1/854). The age of the introduction of c.1580C>G into Iceland is estimated to be around 22 generations [20] [21] [22] .
We also attempted to confirm the new signal at the centromere of chromosome 1 but were unable to get a functioning genotyping assay for chr1_142697422. However, an assay was available for the second-most significant SNP at the locus, chr1_144539240, which is highly correlated with chr1_142697422 (r 2 = 0.76) ( Fig. 1 and  Supplementary Table 3) . We genotyped 1,098 and 1,232 Icelandic individuals with gout and control individuals, respectively, and observed a similar OR and a stronger P value than resulted from the imputed genotypes (OR = 2.21, P = 0.0027). The observed r 2 between the imputed and direct genotypes was 0.63, which is consistent with the estimated imputation information of 0.65 (Supplementary Table 3) , and the observed frequencies of the uric acid-raising allele for this The recent meta-analyses of GWAS for serum uric acid levels, using 2.5 million HapMap markers, yielded 17 SNPs at 9 separate loci 8, 9 ( Table 2 and Supplementary Table 3 ). Among these, only a single SNP at chromosome 6 did not reach nominal significance in our data (Supplementary Table 3) . For all of the SNPs, the allele that associated with increased serum uric acid levels also increased the risk of gout (Fig. 2 and Table 1 ). The SNP in ALDH16A1 and the new SNP in chromosome 1 have the largest effects on the risk of gout and on serum uric acid levels.
There was a substantial difference in serum uric acid levels between the sexes among the control subjects (males 0.36 mM, females 0.29 mM), whereas among individuals with gout, the difference between the sexes was much smaller (males 0.44 mM, females 0.41 mM). The higher level in males was reflected by a higher risk of gout among males. The smaller difference between the sexes among individuals with gout is probably a result of the fact that development of gout is dependent on reaching the saturation point of uric acid in joint fluids, which is most likely similar in both sexes 1, 23 . Interaction between sex and the effect of the SNPs associated with gout and serum uric acid has been reported for the ABCG2 and SLC2A9 loci 4, 8 . We observed similar interactions in our data for these two loci. For the two newly discovered variants at ALDH16A1 and the chromosome 1 centromere, we also observed an interaction with sex for the risk of gout (Fig. 2 and Supplementary  Tables 4 and 5) . However, no significant difference in the effect on serum uric acid levels was observed for either of these two loci, in contrast to the ABCG2 and SLC2A9 loci. Among clinically ascertained gout cases, the alleles associating with increased risk of gout at the ALDH16A1 and ABCG2 loci correlated with an earlier age of visit to the clinician (by 7.6 and 3.4 years, respectively) (Supplementary Table 6 ). A similar trend was observed for the new marker at chromosome 1.
In summary, we have discovered a low-frequency variant in a previously unidentified gout susceptibility locus at 19q13 that has a large effect on serum uric acid levels and gout. We observed a more pronounced association of this variant with gout among males, and the variant also correlates with an earlier age at diagnosis. At a locus flanking the chromosome 1 centromere, we identified a new lowfrequency variant associated with serum uric acid levels. Sequencing the whole genome of large groups of individuals has rapidly become affordable, and whole-genome sequencing efforts (for example, the 1000 Genomes Project) have already generated a large amount of data. The current study illustrates how signals that have gone undetected when only imputations based on the HapMap Project were available can now be found through the imputation of variants based on whole-genome sequencing. The low-frequency variants described here are even rarer in other populations, and the association with these variants would likely have been difficult to find in those populations. The recent rapid growth and the relative homogeneity of the Icelandic population have decreased the diversity and increased the variability of allele frequencies; formerly rare variants have become more common, as is the case here and in our previous report on sick sinus syndrome 20 , but at other times, variants may be rarer or even absent from the Icelandic population.
MeThOdS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession numbers. Sequences have been deposited in the GenBank database for the two mRNA variants of ALDH16A1 (NM_153329, 17-exon transcript; NM_001145396, 16-exon transcript). P.S., D.F.G., G.B.W., H. J., U.T., I.J. and K.S. wrote the manuscript. P.S., D.F.G.,  G.B.W., G.B., H.H., H. 
Note: Supplementary information is available on the Nature Genetics website.
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Gout. The gout sample set, a total of 1,253 Icelanders, was recruited through multiple sources. Subject recruitment. Approval for these studies was provided by the National Bioethics Committee and the Icelandic Data Protection Authority. Informed consent was obtained from all participants. A subset of these individuals (N = 735) were regular users of anti-gout medication corresponding to the Anatomical Therapeutic Chemical Classification System class M04 (ATC-M04). The extent to which subjects used ATC-M04 was determined through questionnaires at the time of study entry into one of the genetics projects at deCODE (N = 517) and/or through medical record information used in the Residence Assessment Instrument (RAI) and Minimum Data Set (MDS) for individuals residing in a nursing home or applying for nursing home care from 1993- Serum uric acid levels. Serum uric acid levels were assessed in blood samples from 22,547 Icelanders at the Landspitali University Hospital Laboratory or at the Icelandic Medical Center (Laeknasetrid) Laboratory in Mjodd (RAM) between 1990 and 2010. Approval for these studies was provided by the National Bioethics Committee and the Icelandic Data Protection Authority. Informed consent was obtained from all participants. Serum uric acid levels were normalized to a standard normal distribution using quantile-quantile normalization and then adjusted for sex, year of birth and age at measurement. For individuals for whom more than one measurement was available, we used the average of the normalized value. Serum uric acid levels are determined from an enzymatic reaction in which uricase oxidizes urate to allantoin and hydrogen peroxide, which with the aid of peroxidase and a dye forms a colored complex that can be measured in a photometer at a wavelength of 670 nm.
Other populations. In order to estimate the frequency of the ALDH16A1 variant c.1580C>G and the chr1_144539240 variant outside of Iceland, we genotyped for these two variants in four other populations using Sanger sequencing and a single-track Centaurus assay, respectively. The first population consisted of 1,538 individuals from the Gentofte area in Denmark participating in a study of chronic obstructive pulmonary disease by the Danish Lung and Cancer Screening Trial 24 . The second population consisted of 699 individuals from Oslo, Norway, originally recruited for a case-control study of schizophrenia 25 . The third population consisted of 1,024 individuals, including 163 Dutch individuals with self-reported gout, from Nijmegen in The Netherlands participating in a cancer case-control study 26 . The fourth population consisted of 854 individuals from Pennsylvania, USA, participating in a sleep apnea case-control study, of whom 46% were of European ancestry.
Illumina genome-wide genotyping. The Icelandic chip-genotyped samples were assayed with the Illumina Human Hap300, Hap CNV370, Hap 610, 1M or Omni-1 Quad bead chips at deCODE genetics. Only the 317,503 SNPs from the Human Hap300 chip were used in long-range phasing and subsequent SNP imputations. SNPs were excluded if (i) yield was lower than 95%, (ii) minor allele frequency was less than 1% in the population, (iii) significant deviation from Hardy-Weinberg equilibrium was observed in the controls (P < 0.001), (iv) an excessive inheritance error rate (over 0.001) was produced or (v) there was a substantial difference in allele frequency between chip types (from just a single chip if that resolved all differences, but from all chips, otherwise). All samples with a call rate below 97% were excluded from the analysis. The final set of SNPs used for long-range phasing was composed of 297,835 autosomal SNPs.
Sanger sequencing. Dye-terminator Sanger sequencing was performed with the Applied Biosystems BigDye Terminator v3.1 Cycle Sequencing Kit, with Agencourt Ampure XP and Agencourt CleanSeq for cleanup of the PCR and cycle sequencing product, respectively. AmpureXP and CleanSeq bead cleaning was performed on a Zymark Sciclone ALH-500 liquid-handling robot system. Tray dilutions for PCR setup and cycle-sequencing setup were prepared on a Packard MultiprobeII HTEX liquid-handling robot system, and genomic DNA and PCR product were transferred into their respective trays using the Zymark Sciclone ALH-500. PCR and cycle sequencing reactions were performed on MJ Research PTC-225 thermal cyclers. For signal detection, Applied Biosystems 3730xl DNA analyzers were used.
Centaurus SNP genotyping. The SNP genotyping of the chr1_144539240 SNP was carried out by deCODE genetics by applying the Centaurus (Nanogen) platform 27 .
Whole-genome sequencing. SNPs were identified through the Icelandic whole-genome sequencing project. A total of 457 Icelanders were selected for sequencing based on having various neoplasic, cardiovascular and psychiatric conditions. All of the individuals were sequenced to a depth of at least 10×. A two-step approach was applied to SNP calling of the whole-genome sequencing data. The first step was to detect SNPs by identifying sequence positions where at least one individual could be determined to be different from the reference sequence with confidence (quality threshold of 20) using the SNP calling feature of the pileup tool from samtools 28 . The second step was to use the pileup tool to genotype the SNPs at the positions that were flagged as polymorphic. Because sequencing depth varies and, therefore, the certainty of genotype calls also varies, genotype likelihoods rather than deterministic calls were calculated. See the Supplementary Note for further information.
Genotype imputation. We imputed the SNPs that were identified and genotyped through sequencing into all Icelanders who had been phased with longrange phasing using the same model as used by IMPUTE 29 . In addition to imputing sequence variants from the whole-genome sequencing effort into chipgenotyped individuals, we also performed a second imputation step in which genotypes were imputed into relatives of chip-genotyped individuals, creating in silico genotypes. See the Supplementary Note for further information.
Association testing. Logistic regression was used to test for association between SNPs and disease, treating disease status as the response and expected genotype counts from imputation or allele counts from direct genotyping as covariates. A generalized form of linear regression was used to test for the association of uric acid levels with SNPs. See the Supplementary Note for further information.
Inflation factor adjustment. To account for the relatedness and stratification within our case and control sample sets, we applied the method of genomic control based on chip markers. For the GWAS on gout and serum uric acid level, the correction factors based on the genomic control were 1.10 and 1.18, respectively. For comparison, we note that for the GWAS on gout and serum uric acid level, when restricting to individuals that were directly chip-genotyped, the correction factors based on the genomic control were 1.05 and 1.14, respectively.
We also estimated the inflation factor using a previously described procedure in which genotypes for the ALDH16A1 missense variants (minor allele frequency = 0.013) were simulated (N = 100,000) through the genealogy of 731,175 Icelanders, and the χ 2 statistic was corrected accordingly 30 . We determined the inflation factor for the set of 1,094 Icelandic individuals with gout and 4,923 control individuals in this study that were directly genotyped by Sanger sequencing to be 1.07, and the P values cited have been adjusted accordingly.
